Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Recordati (RECm)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
49.60 +0.00    +0.00%
19/04 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Euro Zone
ISIN:  IT0003828271 
  • Volume: 0
  • Bid/Ask: 48.98 / 0.00
  • Day's Range: 49.37 - 49.66
Recordati 49.60 +0.00 +0.00%

Recordati Company Profile

 
Get an in-depth profile of Recordati, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

4369

Equity Type

ORD

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.

Contact Information

Address Via Matteo Civitali,1
Milan, 20148
Italy
Phone 39 02 487871
Fax 39 02 40073747

Top Executives

Name Age Since Title
Michaela Castelli 53 2014 Lead Independent Director
Andrea Recordati 52 1998 Non-Executive Chairman
Ezio Maria Simonelli 65 2020 Statutory Auditor
Livia Amidani Aliberti 62 2014 Statutory Auditor
Luigi Felice La Corte 54 2019 Group CFO & Executive Director
Cathrin Petty 50 2018 Executive Director
Antonio Santi 46 2017 Chairman of Statutory Auditor Board
Elisa Corghi 51 2022 Independent Director
Guido Guidi 70 2020 Non-Executive Vice Chairman
Kim Stratton 61 2021 Non-Executive Director
Giampiero Mazza 54 2018 Executive Director
Giorgio De Palma 49 2020 Executive Director
Piergiorgio Peluso 55 2020 Independent Non-Executive Director
Joanna Susan Le Couilliard 60 2019 Independent Non-Executive Director
Robert Koremans 61 2021 CEO & Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RECI Comments

Write your thoughts about Recordati
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alessandro To
Alessandro To Jan 12, 2023 12:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cala giu esco.. 38.70 bariera per
Alessandro To
Alessandro To Dec 12, 2022 9:53AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
42.15 obbiettivo di oggi.
Pau Sanchis
Pau Sanchis May 21, 2020 7:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
...
Pau Sanchis
Pau Sanchis May 19, 2020 9:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hola buenas... posible suelo 40.75?.. q pensais?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email